Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says
Executive Summary
Centocor's efforts to increase tuberculosis screening prior to Remicade therapy are working as intended, Johnson & Johnson VP-Investor Relations Helen Short told an Oct. 16 earnings call.
You may also be interested in...
TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education
FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education
FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
Centocor Remicade "Dear Doctor" Letter Warns Against Use In CHF
Centocor will revise Remicade labeling to warn against use in congestive heart failure after the company completes analysis of Phase II results showing an adverse impact from infliximab.